The search for truly individualized upfront risk data.
Current methods for categorizing patients on the transplant waitlist as low or high risk for post-transplant rejection are overly broad. The problem is that they’re primarily based on general factors such as race, retransplant status, recipient age, and the presence of donor-specific antibodies.
Next level personalized care.
PTRA™ improves this process by using an RNA gene signature to assess each patient’s individual risk of acute rejection during the pre-transplant phase. This approach enables clinicians to potentially tailor immunosuppression strategies with greater precision and personalization.
Stratify Early, Intervene Smarter. Pretransplant Risk Insights:
- Stratifies patients pre-transplant based on their immunological risk categories using a simple blood draw into high vs low risk.
- Supports personalized care planning by helping clinicians anticipate and mitigate potential transplant complications.
- Provides a non-invasive and easily integrated process into existing pretransplant evaluation workflows.
- Built on molecular profiling, thereby providing insights beyond traditional clinical and histocompatibility markers.
For more information, please visit our partner, ThermoFisher.